HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced positive results from a newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). 24 clinical trial sites across the U.S. and 103 unselected subjects participated in the blinded, placebo controlled study.
